Skip to main content

Table 6 Adherence to Follow-Up Among Patients with a Positive Baseline Screen

From: Black patients referred to a lung cancer screening program experience lower rates of screening and longer time to follow-up

Lung-RADS 3  
 Black Patients
n = 21
White Patients
n = 22
Mean Age ± SD65.1 ± 5.765.1 ± 5.0
Sex
• Female11 (52.4%)8 (36.4%)
• Male10 (47.6%)14 (63.6%)
Overall adherencea, n (%)19 (90.5%)20 (90.9%)
Time to follow-up CTb, mean mos ± SD8.5 ± 4.56.6 ± 3.0
Timely adherencec, n (%)12 (63.2%)16 (80.0%)
Screen-detected cancer2 (9.1%)0 (0%)
Patients eligible for screening or nodule surveillance18d21e
• Return to annual screening or nodule surveillance11 (61.1%)12 (57.1%)
• Lost to follow-upf7 (38.9%)9 (42.9%)
Lung-RADS 4
 Black Patients
n = 14
White Patients
n = 13
Mean Age ± SD688 ± 5.865.2 ± 4.3
Sex
• Female5 (35.7%)3 (23.1%)
• Male9 (64.3%)10 (76.9%)
Overall adherencea, n (%)14 (100%)13 (100%)
Time to follow-up CTb, mean mos ± SD3.1 ± 2.92.1 ± 1.5
Timely adherencec, n (%)10 (71.4%)10 (76.9%)
Screen-detected cancer5 (35.7%)3 (30.8%)
Patients eligible for screening or nodule surveillance99
• Return to annual screening or nodule surveillance3 (33.3%)6 (66.7%)
• Lost to follow-upf6 (66.7%)3 (33.3%)
  1. a Overall adherence was defined as any follow-up CT chest following the baseline LDCT
  2. b Time to follow-up was measured among screened patients who were adherent with any follow-up CT
  3. c On-time adherence was defined as a follow-up CT within 30 days of the recommended time-frame for follow-up (4 months for Lung-RADS 3 or 4)
  4. dOne black, Lung-RADS 3 patient became ineligible during the follow-up period due to smoking cessation > 15 years prior
  5. eOne white, Lung-RADS 3 patient died during the follow-up period
  6. f Lost to follow-up was defined by current status